June 2, 2026 -- Tavo Biotherapeutics today announced the successful closing of a $17 million Series A financing led by Pureos Bioventures with participation by Polaris Partners and continued support from existing investor Tau Capital. The proceeds will be used to advance Tavo's pipeline of innovative therapies targeting glaucoma and retinal disease. In conjunction with the financing, Tavo Biotherapeutics also announced the appointment of Federico Grossi, M.D., Ph.D., as Chief Medical Officer, t

Median overall survival, a secondary endpoint, reached nearly 3.5 years with Johnson & Johnson's RYBREVANT® plus LAZCLUZE® in atypical EGFR-mutated disease Consistent responses observed across atypical EGFR mutation subgroups, including those historically associated with poorer outcomes ASCO 2026 results reinforce the significance of RYBREVANT®-based regimens for patients across EGFR mutations May 29, 2026 -- Johnson & Johnson (NYSE:JNJ) today announced updated results from the Phase 1/1b CHRYS

Anthropic has raised $65 billion in Series H funding, bringing its post-money valuation to $965 billion and surpassing OpenAI to become the world's highest-valued private AI company. Altimeter Capital, Dragoneer, Greenoaks, Sequoia Capital, Capital Group, Coatue, D1 Capital Partners, GIC, ICONIQ and XN co-led the round. Other investors in the round include AMP PBC, Baillie Gifford, Blackstone, Brookfield, D.E. Shaw Ventures, DST Global, Fidelity Management & Research Company, General Catalyst,

Pfizer continues its dealmaking spree by striking a back-heavy partnership with China’s Innovent Biologics to assemble a pipeline of antibody-based therapies for cancer. Pfizer is teaming up with China’s Innovent Biologics to advance a broad pipeline of cancer therapies, continuing the New York pharma’s recent dealmaking spree. Under the terms of the agreement, announced late on Thursday, Pfizer will make a $650 million upfront payment and offer up to $9.85 billion in development, regulatory a

Financing Provides Immediate Growth Capital to Support Clinical Development Initiatives and Extends Projected Operating Cash Runway for Over Two (2) Years May 28, 2026 -- Medicus Pharma Ltd. (NASDAQ: MDCX) (“Medicus” or the “Company”), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, today announced that it has entered into a definitive financing agreement with an institutional investor providing for

Repeat medtech founder and operator behind multiple nine-figure exits launches investment and strategic advisory platform to help founders build, fund and scale medical device companies May 28, 2026 -- John Slump, co-founder and former president and CEO of Atraverse Medical, announced the launch of Metis MedTech, an investment and strategic advisory platform for medical device founders. The launch follows the close of Johnson & Johnson's acquisition of Atraverse Medical on May 15, 2026, which s

Collaboration integrates AI discovery, human brain organoid modeling, and in vivo validation to generate differentiated neurology assets for pharmaceutical partnering and development May 28, 2026 -- Lunai Bioworks' (NASDAQ: LNAI) wholly owned subsidiary BioSymetrics and BrainStorm Therapeutics today announced a strategic collaboration and Letter of Intent (LOI) to jointly discover, validate, and advance novel therapeutic targets for neurological diseases. The collaboration is supported by a new

May 28, 2026 -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) today announced that the Phase II clinical study of its proprietary PD-L1/4-1BB bispecific antibody, Opamtistomig (LBL-024), in combination with chemotherapy for the first-line treatment of non-small cell lung cancer (NSCLC), has been selected for an oral presentation at the 2026 World Conference on Lung Cancer (WCLC), the world's most influential scientific meeting in the lung cancer field,

GSK's investigational chronic hepatitis B therapy bepirovirsen was associated with a near one-in-five functional cure response rate across a pair of Phase III studies, results the company called "unprecedented." The findings from the B-Well 1 and B-Well 2 trials were presented Thursday at the European Association for the Study of the Liver (EASL) congress and published in the NEJM. "For the first time, bepirovirsen offers the possibility of significantly better functional cure rates than the cu

May 28, 2026 -- Denteric today announced the commencement of participant recruitment for a Phase I clinical study of its first-in-class therapy for Alzheimer's disease. Alzheimer's disease remains one of the greatest medical challenges of our time and with an aging population this will only increase. Approximately 38 million people globally and 7 million in the US alone live with Alzheimer's disease. A growing body of research links the progression of Alzheimer's disease with exposure to chron